MANGOCEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| For The Three Months Ended September 30, 2025 | For The Three Months Ended September 30, 2024 | For The Nine Months Ended September 30, 2025 | For The Nine Months Ended September 30, 2024 | |
|---|---|---|---|---|
| Revenues | ||||
| Revenues | $84,246 | $133,368 | $361,661 | $510,626 |
| Cost of revenues | 2,359 | 21,505 | 45,911 | 71,965 |
| Cost of revenues - related party | 30,988 | 29,192 | 112,839 | 138,800 |
| Gross profit | 50,899 | 82,671 | 202,911 | 299,861 |
| Operating expenses | ||||
| General and administrative expenses | 311,379 | 523,855 | 3,099,183 | 2,146,517 |
| Salary and benefits | 542,420 | 242,941 | 1,797,361 | 795,255 |
| Advertising and marketing | 104,914 | 251,330 | 644,941 | 1,332,957 |
| Investor relations | 33,319 | 255,000 | 1,558,319 | 438,000 |
| Stock based compensation | 6,601,793 | 567,619 | 10,767,717 | 1,881,464 |
| Total operating expenses | 7,593,825 | 1,840,745 | 17,867,521 | 6,594,193 |
| Loss from operations | (7,542,926) | (1,758,074) | (17,664,610) | (6,294,332) |
| Other (income) expense | ||||
| Interest expense | 75,850 | - | 83,850 | - |
| Interest expense - amortization on discount | - | 241,620 | - | 464,298 |
| Loss from settlement | - | - | 125,625 | - |
| Total other (income) expense | 75,850 | 241,620 | 209,475 | 464,298 |
| Loss before income taxes | (7,618,776) | (1,999,694) | (17,874,085) | (6,758,630) |
| Income taxes | - | - | - | - |
| Net loss | (7,618,776) | (1,999,694) | (17,874,085) | (6,758,630) |
| Net loss attributed to non-controlling interest | (558) | (461) | (658) | (837) |
| Net loss attributed to Mangoceuticals, Inc. | (7,618,218) | (1,999,233) | (17,873,427) | (6,757,793) |
| Preferred stock dividend requirements | 294,000 | 294,000 | 882,000 | 802,109 |
| Net loss attributed to Mangoceuticals, Inc. common stockholders | $(7,912,218) | $(2,293,233) | $(18,755,427) | $(7,559,902) |
| Basic and diluted loss per share | ||||
| Basic and diluted loss per share | $(0.69) | $(1.14) | $(2.16) | $(4.28) |
| Weighted average number of shares outstanding | ||||
| Basic and diluted | 11,524,275 | 2,013,848 | 8,699,144 | 1,765,051 |
Mangoceuticals, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income
| For the Three Months Ended September 30, 2025 | For the Three Months Ended September 30, 2024 | For the Nine Months Ended September 30, 2025 | For The Nine Months Ended September 30, 2024 | |
|---|---|---|---|---|
| Net loss | $(7,618,776) | $(1,999,694) | $(17,874,085) | $(6,758,630) |
| Other comprehensive income (loss) | ||||
| Foreign currency translation adjustments | (45) | (497) | (2,079) | (1,663) |
| Comprehensive loss | (7,618,821) | (2,000,191) | (17,876,164) | (6,760,293) |
| Less comprehensive loss attributed to non-controlling interest | (558) | (461) | (658) | (837) |
| Comprehensive loss attributable to Mangoceuticals, Inc. stockholders | $(7,618,263) | $(1,999,730) | $(17,875,506) | $(6,759,456) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.